https://medicine.iu.edu/expertise/precision-health/multiple-myeloma
Multiple myeloma research at IU School of Medicine. ... Indiana University School of Medicine. 340 West 10th Street Fairbanks Hall, Suite 6200 Indianapolis, IN 46202-3082 317-274-8157 iusm@iu.edu. Connect with us! Facebook. Instagram. LinkedIn

https://medicine.iu.edu/give/cancer-research/multiple-myeloma
Multiple Myeloma Research. Researchers at Indiana University are going the distance to find a cure for multiple myeloma. ... Indiana University School of Medicine. 340 West 10th Street Fairbanks Hall, Suite 6200 Indianapolis, IN 46202-3082 317-274-8157 iusm@iu.edu. Connect with us! Facebook

https://medicine.iu.edu/news/2023/04/cancer-center-first-human-multiple-myeloma-study
Suvannasankha is part of the multiple myeloma research group at the IU Simon Comprehensive Cancer Center, ... Indiana University School of Medicine. 340 West 10th Street Fairbanks Hall, Suite 6200 Indianapolis, IN 46202-3082 317-274-8157 iusm@iu.edu. Connect with us!

https://cancer.iu.edu/research/programs/hhm/index.html
Dr. Suvannasankha, the Carol Edwards Associate Professor of Clinical Medicine at IU School of Medicine, was recently appointed co-chair of the Big Ten Cancer Research Consortium's Multiple Myeloma Clinical Trial Working Group. Cancer. 2021 Nov Lancet Oncol. 2020 Feb

https://cancer.iu.edu/patients/research-explained/multiple-myeloma/index.html
The annual Miles for Myeloma bicycling event has generated more than $6 million in community donations for myeloma research. When he's wearing his white lab coat, Dr. Abonour directs the multiple myeloma team for IU Precision Health - one of the university's Grand Challenge initiatives.

https://iuhealth.org/find-medical-services/multiple-myeloma
Evolving Multiple Myeloma Treatment Protocols. Our teams combine their unparalleled clinical expertise using cellular therapy to treat multiple myeloma with innovative, ongoing clinical trials with the IU School of Medicine. These clinical trials aim to prevent and cure this cancer using cell-based immunotherapy. Clinical trials include:

https://cancer.iu.edu/giving/updates/myeloma.html
At the IU Simon Comprehensive Cancer Center, we are striving to find answers about multiple myeloma. Our physicians and researchers work at the cutting edge, using the latest advances in genomic sequencing, machine learning and drug discovery. They also lead clinical trials for the newest options in immunotherapy.

https://ascopost.com/issues/may-25-2020/indiana-university-researcher-receives-nci-grant-for-multiple-myeloma/
G. David Roodman, MD, PhD, of Indiana University (IU) Melvin and Bren Simon Comprehensive Cancer Center, has been awarded a 5-year, $1.6 million grant from the National Cancer Institute (NCI) to study ways to build bone and decrease tumor growth in multiple myeloma bone disease. Dr. Roodman is Professor at IU School of Medicine. He is leading the research to investigate a molecule developed

https://medicine.iu.edu/magazine/tracing-the-story-of-myeloma
Researchers at IU School of Medicine explore every facet of multiple myeloma-from the lab bench to the clinic. To support work that enhances care, contact Amber Kleopfer Senseny at 317-278-4510 or akelopfe@iu.edu.

https://journals.indianapolis.iu.edu/index.php/IMPRS/article/view/24807
However, their impact in hematological malignancies remains unclear. We sought to determine how muscle phenotype relates to survival in patients with multiple myeloma. Methods: We performed a retrospective review of patients with multiple myeloma treated at Indiana University Hospital from 2012-2016. Total skeletal muscle area (SMA) (cm2) and

https://www.newswise.com/articles/iu-cancer-center-researcher-leads-first-in-human-multiple-myeloma-study-with-90-5-percent-response-rate
Indiana University Melvin and Bren Simon Comprehensive Cancer Center served as the lead site for a promising first-in-human clinical trial for patients with rel

https://news.iu.edu/live/news/35646-international-scholar-feature-cancer-immunotherapy
The Christopher Brown Professor of Immunology at the Indiana University School of Medicine, Apetoh speaks from experience. ... which translates IU research into clinical trials targeting multiple myeloma and triple negative breast cancer — two conditions that often resist standard cancer treatment.

https://iu.cloud-cme.com/FocusonMultipleMyelomaPart1
Indiana University School of Medicine, Continuing Medical Education , Focus on Multiple Myeloma Part I, 4/2/2021 12:00:00 AM - 4/2/2022 12:00:00 AM, Launch Date: 4/2/2021 Expiration Date : 4/2/2022 ... Harry and Edith Gladstein Professor of Cancer Research Indiana University. Faculty. Consultant-PI of clinical trial, steering committee-Bristol

https://ipe.iu.edu/sitecore/content/iu/iu-som/home/news/2023/04/cancer-center-first-human-multiple-myeloma-study
Indiana University Melvin and Bren Simon Comprehensive Cancer Center served as the lead site for a promising first-in-human clinical trial for patients with relapsed multiple myeloma. IU Simon Comprehensive Cancer Center Apr 17, 2023

https://medicine.iu.edu/news/2020/05/nci-grant-for-multiple-myeloma-bone-disease-therapies
IU School of Medicine May 11, 2020. INDIANAPOLIS - An Indiana University Melvin and Bren Simon Comprehensive Cancer Center researcher has been awarded a five-year, $1.6 million grant from the National Cancer Institute to study ways to build bone and decrease tumor growth in multiple myeloma bone disease. Multiple myeloma is a blood cancer

https://www.youtube.com/watch?v=F93-enLgNYI
Researchers at IU School of Medicine are studying ways to prevent a rare form of cancer, multiple myeloma, in bariatric weight loss patients through research

https://pubmed.ncbi.nlm.nih.gov/38942927/
Multiple myeloma (MM) is a plasma cell malignancy of the bone marrow. Despite therapeutic advances, MM remains incurable, and better risk stratification as well as new therapies are therefore highly needed. The proteome of MM has not been systematically assessed before and holds the potential to unc

https://cancer.iu.edu/about/members/bio/29680
His multiple myeloma expertise is invaluable to the IU team, a multidisciplinary team of researchers and clinicians working to cure the blood cancer. Two other teams are concentrating on developing cures for triple negative breast cancer and childhood sarcoma.

https://cancer.iu.edu/community/m4m/index.html
Supporting multiple myeloma research and patient care. For 19 years and counting, Dr. Rafat Abonour and his supporters have set out on the annual Miles for Myeloma campaign. This inspiring crew is made up of myeloma researchers and medical caregivers, family members of patients and even a couple of patients themselves.

https://www.nature.com/articles/s41598-024-65590-4
Multiple myeloma (MM) is a plasma cell disorder accounting for approximately 10% of hematologic malignancies. There is limited epidemiological evidence regarding the long-term trends and

https://medicine.iu.edu/give/cancer-research/multiple-myeloma/going-the-extra-mile
Back in 2005, grant funding for multiple myeloma research was scarce. Abonour knew philanthropy—with its ability to fund new ideas and produce data that can prompt grants—was crucial to his cause. ... Indiana University School of Medicine. 340 West 10th Street Fairbanks Hall, Suite 6200 Indianapolis, IN 46202-3082 317-274-8157 iusm@iu.edu

https://scholarworks.indianapolis.iu.edu/bitstreams/2c95fdc1-16f4-441e-b33f-f38e6a919edd/download
Role of Sphingolipids in Multiple Myeloma Progression, Drug Resistance, and Their Potential as Therapeutic Targets Daniela N. Petrusca1*, Kelvin P. Lee1,2 and Deborah L. Galson3 1 Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, IN, United States, 2 Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis

https://medicine.iu.edu/blogs/precision-health/Third-IU-Precision-Health-Initiative-webinar-focuses-on-multiple-myeloma-progress
The third IU Grand Challenges webinar about the Precision Health Initiative (PHI) took place in October, focusing on progress in studying and treating multiple myeloma, which is a cancer of the plasma cells in blood. This webinar featured Rafat Abonour, MD, who leads the IU Precision Health Initiative multiple myeloma disease research team, as well as Dorothy Frapwell, a multiple myeloma

https://cancer.iu.edu/community/m4m/get-involved.html
You may also send a tax-deductible contribution payable to IUF/Miles for Myeloma Fund. Mail your gift to: IU School of Medicine c/o IU Foundation PO Box 7072 Indianapolis, IN 46207-7072 If you have specific questions about how your donation or the funds you raise will be used, our team members can discuss our ongoing research and clinical care